Valproate-Associated Hyperammonaemic Encephalopathy.
Anthonipillai P, Sharp G, Kimber J, Ziauddin V.
Acute Med. 2022;21(1):43-46. doi: 10.52964/AMJA.0891.
Drug-Induced Liver Injury.
Almario EE, Borlak J, Suzuki A, Chen M.
Biomed Res Int. 2017;2017:2461694. doi: 10.1155/2017/2461694. Epub 2017 Jan 9.
Sodium valproate-related hyperammonaemic encephalopathy.
Pegg EJ, Zaman F.
BMJ Case Rep. 2014 Apr 10;2014:bcr2014203899. doi: 10.1136/bcr-2014-203899.
Valproate poisoning.
Garnier R, Boudignat O, Fournier PE.
Lancet. 1982 Jul 10;2(8289):97. doi: 10.1016/s0140-6736(82)91713-5.
Hyperammonaemic encephalopathy.
Chetwood JD, Koorey D, Bryant C.
Intern Med J. 2022 Apr;52(4):693-694. doi: 10.1111/imj.15738.
Sodium valproate and the liver.
[No authors listed]
Lancet. 1980 Nov 22;2(8204):1119-20.
Valproic Acid Poisoning.
Mekonnen S.
J Emerg Nurs. 2019 Jan;45(1):98-100. doi: 10.1016/j.jen.2018.11.003.
Valproate tremors.
Karas BJ, Wilder BJ, Hammond EJ, Bauman AW.
Neurology. 1982 Apr;32(4):428-32. doi: 10.1212/wnl.32.4.428.
Toxin-induced hepatic injury.
Lopez AM, Hendrickson RG.
Emerg Med Clin North Am. 2014 Feb;32(1):103-25. doi: 10.1016/j.emc.2013.09.005.
Modulation of keap-1/Nrf2/HO-1 and NF-qb/caspase-3 signaling pathways by dihydromyricetin ameliorates sodium valproate-induced liver injury.
Emad D, Bayoumi AMA, Gebril SM, Ali DME, Waz S.
Arch Biochem Biophys. 2024 Aug;758:110084. doi: 10.1016/j.abb.2024.110084. Epub 2024 Jul 4.
